- $190.36m
- $71.47m
- $335.71m
- 62
- 67
- 71
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 1.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.95% | ||
| Return on Equity | -14.1% | ||
| Operating Margin | -9.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 308.49 | 358 | 377.24 | 315.66 | 335.7 | 353.7 | 375.7 | -1.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. It offers Simeox, which is an airway clearance device.
Directors
- Elizabeth Mora CHM (60)
- Nabil Shabshab PRE (55)
- Brenton Taylor CFD (39)
- Michael Sergesketter CFO (60)
- Stanislav Glezer EVP (49)
- Jason Somer EVP
- George Parr EVP (50)
- Bart Sanford EVP (55)
- Heath Lukatch DRC (54)
- Benjamin Anderson-Ray IND (66)
- Loren McFarland IND (62)
- Kristen Miranda IND (59)
- Heather Rider IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 27th, 2001
- Public Since
- February 14th, 2014
- No. of Shareholders
- 8
- No. of Employees
- 766
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 26,887,242
- Address
- 859 WARD DRIVE, GOLETA, 93111
- Web
- https://www.inogen.com/
- Phone
- +1 8055620500
- Contact
- Ryan Peterson
- Auditors
- Deloitte & Touche LLP
Upcoming Events for INGN
Q3 2025 Inogen Inc Earnings Release
Similar to INGN
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Inogen share price?
As of Today at 21:18 UTC, shares in Inogen are trading at $7.08. This share price information is delayed by 15 minutes.
How has the Inogen share price performed this year?
Shares in Inogen last closed at $7.08 and the price had moved by -11.17% over the past 365 days. In terms of relative price strength the Inogen share price has underperformed the S&P500 Index by -21.42% over the past year.
What are the analyst and broker recommendations for Inogen?
The overall consensus recommendation for Inogen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inogen dividend yield?
Inogen does not currently pay a dividend.
Does Inogen pay a dividend?
Inogen does not currently pay a dividend.
When does Inogen next pay dividends?
Inogen does not currently pay a dividend.
How do I buy Inogen shares?
To buy shares in Inogen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inogen?
As of the previous close price of $7.08, shares in Inogen had a market capitalisation of $190.36m.
Where are Inogen shares listed?
Here are the trading details for Inogen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INGN
What kind of share is Inogen?
Based on an overall assessment of its quality, value and momentum Inogen is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inogen share price forecast for 2025?
The analyst consensus target price for shares in Inogen is $13.00. That is 83.62% above the last closing price of $7.08.
Analysts covering Inogen currently have a consensus Earnings Per Share (EPS) forecast of -$1.04 for the next financial year.
Find out moreWhat is the trend in the Inogen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inogen. Over the past six months, its share price has underperformed the S&P500 Index by -21.04%.
As of the last closing price of $7.08, shares in Inogen were trading -18.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inogen PE Ratio?
The Inogen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inogen?
Inogen's management team is headed by:
- Elizabeth Mora - CHM
- Nabil Shabshab - PRE
- Brenton Taylor - CFD
- Michael Sergesketter - CFO
- Stanislav Glezer - EVP
- Jason Somer - EVP
- George Parr - EVP
- Bart Sanford - EVP
- Heath Lukatch - DRC
- Benjamin Anderson-Ray - IND
- Loren McFarland - IND
- Kristen Miranda - IND
- Heather Rider - IND